Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN52513758
ISRCTN52513758
Completed
Phase 4

Abiraterone acetate plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: multicentre Italian real life” study

rology Department ASL Abruzzo 20 sites145 target enrollmentMay 23, 2016
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
rology Department ASL Abruzzo 2
Enrollment
145
Status
Completed
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

2017 Results article in https://www.ncbi.nlm.nih.gov/pubmed/29126389 results

Registry
who.int
Start Date
May 23, 2016
End Date
November 30, 2017
Last Updated
4 years ago
Study Type
Observational
Sex
Male

Investigators

Sponsor
rology Department ASL Abruzzo 2

Eligibility Criteria

Inclusion Criteria

  • •1\. Men over the age of 18
  • •2\. Biochemically or histologically confirmed progressive mCRPC
  • •3\. Castrate levels of testosterone (\<50 ng/dl)
  • •4\. Chemonaive
  • •5\. Eligible for abiraterone acetate

Exclusion Criteria

  • •Does not meet the inclusion criteria

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific AntigenProstate CancerProstatic Neoplasm
NCT01314118Janssen Biotech, Inc.131
Active, not recruiting
Phase 2
Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate CancerCastration-Sensitive Prostate CarcinomaMetastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
NCT04267887OHSU Knight Cancer Institute7
Completed
Phase 1
A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate CancerProstate Neoplasms
NCT01017939Janssen Research & Development, LLC34
Completed
Phase 1
A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate CancerProstate Neoplasms
NCT00910754Janssen Research & Development, LLC33
Completed
Phase 3
A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based ChemotherapyProstate Neoplasms
NCT01695135Janssen Research & Development, LLC214